Affidea Groups Joins Forces with Reset Health
Affidea is thrilled to announce a new partnership with Reset Health to introduce the Roczen platform, aimed at transforming the management of obesity and type 2 diabetes. This collaboration signifies a notable advancement in patient care, combining clinical expertise with digital innovation.
Revolutionizing Diabetes Management
This partnership will provide an opportunity for patients to engage with a clinically-led, data-driven care pathway. By utilizing advanced analytics, the Roczen platform offers evidence-based interventions that significantly improve health outcomes for those battling obesity and chronic conditions linked to it.
What the Roczen Platform Offers
Designed as an entirely digital experience under the guidance of healthcare professionals, the Roczen platform focuses on delivering sustainable lifestyle changes along with innovative medical treatments. The platform features:
- A comprehensive support pathway designed specifically for patients.
- Continuous monitoring of crucial health metrics to facilitate timely interventions.
- Personalized treatment plans that are adaptable based on individual patient data.
- Direct channels of communication between patients and their healthcare providers for enhanced management and steady support.
- Programs promoting sustainable behavior changes, including dietary modifications and mental wellness.
- Access to GLP-1 medications for eligible patients, facilitating thorough chronic disease management.
Growth in Clinical Services
Affidea’s alliance with Reset Health highlights its commitment to expanding clinical services that cater to the rising demand for effective weight management and diabetes care solutions. The integration of innovative therapeutic options aligns with Affidea's clinical mission to provide patient-focused care, ensuring that every patient has access to the latest treatments.
Expert Insights
Dr. Charles Niehaus, Executive Director at Affidea Group, expressed enthusiasm regarding the initiative: "At Affidea, we prioritize high-quality, tailored care for our patients. With the Roczen platform, we offer a clinically validated approach that allows us to combat two significant health crises present today. We empower our patients to take charge of their health and enhance their quality of life by providing individualized, evidence-based solutions."
Dr. David Wong, Chairman of Reset Health, emphasized the significance of the partnership, stating: "We are excited to collaborate with Affidea to deliver high-quality, clinically-proven care across Europe. By facilitating access to the Roczen model, we can provide personalized support for those living with obesity and type 2 diabetes to ensure that their care meets individual needs."
The Obesity Crisis
According to the World Health Organization, obesity is a growing concern that affects nearly 60% of adults across Europe, with projections indicating an increase by 10-15% by 2030. Obesity is closely linked with type 2 diabetes, where approximately 80-90% of those afflicted are either overweight or classified as obese.
The repercussions of obesity extend beyond physical health, as it is associated with serious medical conditions like osteoarthritis, sleep apnea, and even dementia. Addressing this public health challenge necessitates effective intervention strategies, such as those now offered through the Roczen platform.
About Affidea
Affidea is a leading pan-European provider of community-based polyclinics, advanced diagnostics, and specialist services. Established in 1991, the organization operates approximately 380 centers across numerous countries, delivering essential medical services to nearly 14 million patients annually. Affidea has consistently garnered recognition for its commitment to patient safety and quality care, with over 90% of its facilities honored for excellence in diagnostic imaging.
About Reset Health
Reset Health specializes in digital health innovations, providing scalable clinical solutions that enhance personalized lifestyle interventions. The Roczen platform, in conjunction with breakthrough medications, improves the health outcomes of individuals living with obesity and related comorbidities.
Frequently Asked Questions
What is the Roczen platform?
The Roczen platform is a doctor-led digital care model aimed at managing obesity and type 2 diabetes through personalized treatment and support.
How does Affidea's partnership with Reset Health benefit patients?
This partnership allows patients to access advanced digital tools and personalized care pathways for better management of their health conditions.
What are GLP-1 medications?
GLP-1 medications are a class of drugs used to enhance diabetes management and promote weight loss in individuals with obesity.
Why is obesity a significant health concern?
Obesity is linked to various serious health issues, including type 2 diabetes, heart disease, and mental health problems, making it a critical public health crisis.
How can patients engage with the Roczen platform?
Patients can interact with the Roczen platform through personalized treatment plans, ongoing support from healthcare providers, and joining health monitoring initiatives.
